Literature DB >> 7915964

Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content.

J Prat1, E Oliva, E Lerma, M Vaquero, X Matías-Guiu.   

Abstract

BACKGROUND: Uterine papillary serous adenocarcinoma (UPSA) is a highly aggressive neoplasm with a great tendency for dissemination. p53 and c-erbB-2 immunoreactivity and DNA ploidy are considered to be indicators of prognosis for endometrial carcinomas.
METHODS: Ten cases of patients with UPSA are reported. An attempt to relate pathologic findings with immunohistochemical stains for p53- and c-erbB-2-associated proteins, ploidy, and survival was made.
RESULTS: Three patients were classified as having Stage I; three, Stage II; two, Stage III; and two, Stage IV. Myometrial invasion was present with nine tumors and involved over 50% of the myometrial thickness in five. Uterine lymph vessel invasion was detected in seven cases. Peritoneal spread occurred in six patients. Overexpression of p53 was observed in six tumors, immunoreactivity for c-erbB-2 in four, and aneuploidy in seven. However, only peritoneal spread correlated significantly with survival (P < 0.005).
CONCLUSIONS: UPSA is a tumor with a high metastatic potential that exhibits immunoreactivity for p53 and c-erbB-2 and aneuploidy more often than that reported for conventional endometrioid adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7915964     DOI: 10.1002/1097-0142(19940915)74:6<1778::aid-cncr2820740621>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  The emerging genomic landscape of endometrial cancer.

Authors:  Matthieu Le Gallo; Daphne W Bell
Journal:  Clin Chem       Date:  2013-10-29       Impact factor: 8.327

Review 2.  Practical issues in the diagnosis of serous carcinoma of the endometrium.

Authors:  Sonia Gatius; Xavier Matias-Guiu
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

3.  p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.

Authors:  H Tashiro; C Isacson; R Levine; R J Kurman; K R Cho; L Hedrick
Journal:  Am J Pathol       Date:  1997-01       Impact factor: 4.307

4.  Insights into endometrial serous carcinogenesis and progression.

Authors:  Oluwole Fadare; Wenxin Zheng
Journal:  Int J Clin Exp Pathol       Date:  2009-01-10

5.  Comparison of benign and malignant endometrial lesions for their p53 state, using immunohistochemistry and temperature-gradient gel electrophoresis.

Authors:  L Riethdorf; C Begemann; S Riethdorf; K Milde-Langosch; T Löning
Journal:  Virchows Arch       Date:  1996-04       Impact factor: 4.064

6.  The genomics and genetics of endometrial cancer.

Authors:  Andrea J O'Hara; Daphne W Bell
Journal:  Adv Genomics Genet       Date:  2012-03

7.  Co-expression of survivin, c-erbB2, and cyclooxygenase-2 (COX-2): prognostic value and survival of endometrial cancer patients.

Authors:  Maria Lambropoulou; Nikolaos Papadopoulos; Grigoris Tripsianis; George Alexiadis; Olga Pagonopoulou; Anastasia Kiziridou; Vassilios Liberis; Stylianos Kakolyris; Ekaterini Chatzaki
Journal:  J Cancer Res Clin Oncol       Date:  2009-09-16       Impact factor: 4.553

8.  Clinicopathological characteristics and her-2/neu status in chinese patients with uterine papillary serous carcinoma.

Authors:  Yulan Ren; Huaying Wang; Xiaoyan Zhou; Wentao Yang; Xiaowei Huang; Yongming Lu; Daren Shi
Journal:  ISRN Obstet Gynecol       Date:  2010-10-20

9.  Sequencing of candidate chromosome instability genes in endometrial cancers reveals somatic mutations in ESCO1, CHTF18, and MRE11A.

Authors:  Jessica C Price; Lana M Pollock; Meghan L Rudd; Sarah K Fogoros; Hassan Mohamed; Christin L Hanigan; Matthieu Le Gallo; Suiyuan Zhang; Pedro Cruz; Praveen F Cherukuri; Nancy F Hansen; Kirk J McManus; Andrew K Godwin; Dennis C Sgroi; James C Mullikin; Maria J Merino; Philip Hieter; Daphne W Bell
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.